Czech
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Aurinia Renal Response in Active Lupus With Voclosporin

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Odkaz je uložen do schránky
PostaveníDokončeno
Sponzoři
Aurinia Pharmaceuticals Inc.

Klíčová slova

Abstraktní

The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.

Popis

The aim of the current study is to investigate whether voclosporin, added to the standard of care treatment in active lupus nephritis (LN), is able to reduce disease activity over a treatment period of 52 weeks. The background therapy will be MMF and initial treatment with IV methylprednisolone, followed by a reducing course of oral corticosteroids. Subjects with active, flaring LN will be eligible to enter the study. They are required to have a diagnosis of LN according to established diagnostic criteria and clinical and biopsy features suggestive of active nephritis. Efficacy will be assessed by the ability of the drug combination to reduce the level of proteinuria (as measured by urine protein/creatinine ratio (UPCR)) while demonstrating an acceptable safety profile.

Termíny

Poslední ověření: 10/31/2019
První předloženo: 01/11/2017
Odhadovaná registrace vložena: 01/12/2017
První zveřejnění: 01/15/2017
Poslední aktualizace byla odeslána: 11/18/2019
Poslední aktualizace zveřejněna: 11/19/2019
Aktuální datum zahájení studie: 05/16/2017
Odhadované datum dokončení primární: 09/23/2019
Odhadované datum dokončení studie: 10/09/2019

Stav nebo nemoc

Lupus Nephritis

Intervence / léčba

Drug: Voclosporin

Drug: Placebo Oral Capsule

Fáze

Fáze 3

Skupiny zbraní

PažeIntervence / léčba
Experimental: Voclosporin
oral, 23.7 mg BID
Drug: Voclosporin
calcineurin inhibitor
Placebo Comparator: Placebo Oral Capsule
Voclosporin placebo, oral, 3 capsules BID
Drug: Placebo Oral Capsule
matching placebo capsule

Kritéria způsobilosti

Věky způsobilé ke studiu 18 Years Na 18 Years
Pohlaví způsobilá ke studiuAll
Přijímá zdravé dobrovolníkyAno
Kritéria

Key Inclusion Criteria:

- Subjects with evidence of active nephritis, defined as follows:

- Kidney biopsy result within 2 years prior to screening indicating Class III, IV-S, IV-G (alone or in combination with Class V), or Class V LN with a doubling or greater increase of UPCR within the last 6 months to a minimum of ≥1.5 mg/mg for Class III/IV or to a minimum of ≥2 mg/mg for Class V at screening. Biopsy results over 6 months prior to screening must be reviewed with a medical monitor to confirm eligibility.

OR

- Kidney biopsy result within 6 months prior to screening indicating Class III, IV-S or IV-G (alone or in combination with Class V) LN with a UPCR of ≥1.5 mg/mg at screening.

OR

- Kidney biopsy result within 6 months prior to screening indicating Class V LN and a UPCR of ≥2 mg/mg at screening.

- Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.

Exclusion Criteria:

- Estimated glomerular filtration rate (eGFR) of ≤45 mL/minute at screening.

- Current or medical history of:

- Congenital or acquired immunodeficiency.

- In the opinion of the Investigator, clinically significant drug or alcohol abuse within 2 years prior to screening.

- Malignancy within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision.

- Lymphoproliferative disease or previous total lymphoid irradiation.

- Severe viral infection or known HIV infection.

- Active tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.

- Other known clinically significant active medical conditions, such as:

- Severe cardiovascular disease, liver dysfunction or chronic obstructive pulmonary disease or asthma requiring oral steroids or any other overlapping autoimmune condition for which the condition or the treatment of the condition may affect the study assessments or outcomes.

Výsledek

Primární výsledná opatření

1. The number of subjects achieving renal response [52 Weeks]

The number of subjects achieving renal response

Měření sekundárních výsledků

1. Time to UPCR of ≤0.5 mg/mg. [52 Weeks]

Time to UPCR of ≤0.5 mg/mg.

2. Partial renal response [Weeks 24 and 52]

Partial renal response

3. Time to 50% reduction in UPCR from baseline. [52 Weeks]

Time to 50% reduction in UPCR from baseline.

4. Renal response at Week 52 [52 Weeks]

Renal response at Week 52

5. Duration of renal response [52 Weeks]

Duration of renal response

6. Change from baseline in laboratory parameters at each time point [52 Weeks]

Change from baseline in laboratory parameters at each time point

7. Renal response with low-dose steroids [52 Weeks]

Renal response with low-dose steroids

8. Quality of Life questionnaires [Weeks 12, 24 and 52]

Quality of Life questionnaires

9. Change from baseline in the SELENA-SLEDAI Index score [Weeks 24 and 52]

Change from baseline in the SELENA-SLEDAI Index score

Připojte se k naší
facebookové stránce

Nejúplnější databáze léčivých bylin podložená vědou

  • Funguje v 55 jazycích
  • Bylinné léky podporované vědou
  • Rozpoznávání bylin podle obrázku
  • Interaktivní mapa GPS - označte byliny na místě (již brzy)
  • Přečtěte si vědecké publikace související s vaším hledáním
  • Hledejte léčivé byliny podle jejich účinků
  • Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty

Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu

Google Play badgeApp Store badge